Analysts expect that Guardant Health Inc (NASDAQ:GH) will report ($0.34) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Guardant Health’s earnings, with the lowest EPS estimate coming in at ($0.36) and the highest estimate coming in at ($0.33). The firm is expected to announce its next quarterly earnings results on Thursday, August 8th.
According to Zacks, analysts expect that Guardant Health will report full year earnings of ($1.48) per share for the current fiscal year, with EPS estimates ranging from ($1.51) to ($1.42). For the next financial year, analysts forecast that the business will report earnings of ($1.02) per share, with EPS estimates ranging from ($1.41) to ($0.76). Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Guardant Health.
Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.05. The firm had revenue of $36.66 million during the quarter, compared to analysts’ expectations of $32.12 million.
A number of equities research analysts recently issued reports on the stock. Canaccord Genuity dropped their price objective on shares of Yamana Gold from C$5.50 to C$4.25 in a report on Tuesday, April 16th. Cowen upped their price objective on shares of Guardant Health from $40.00 to $70.00 and gave the company an “outperform” rating in a report on Wednesday, April 3rd. Zacks Investment Research raised shares of Garrett Motion from a “sell” rating to a “hold” rating in a report on Friday, May 10th. JPMorgan Chase & Co. set a €52.00 ($60.47) price objective on shares of Vonovia and gave the company a “buy” rating in a report on Friday, May 10th. Finally, Bank of America set a $25.00 price objective on shares of Bed Bath & Beyond and gave the company a “buy” rating in a report on Wednesday, April 10th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $83.50.
Shares of GH traded down $4.46 during mid-day trading on Friday, reaching $85.05. The stock had a trading volume of 14,073 shares, compared to its average volume of 714,905. Guardant Health has a 52-week low of $27.04 and a 52-week high of $106.58. The company has a fifty day moving average of $85.06. The stock has a market capitalization of $7.63 billion and a price-to-earnings ratio of -30.38.
In other Guardant Health news, CEO Helmy Eltoukhy sold 90,000 shares of the stock in a transaction dated Monday, April 22nd. The shares were sold at an average price of $65.28, for a total transaction of $5,875,200.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Richard B. Lanman sold 3,842 shares of the stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $64.84, for a total transaction of $249,115.28. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 975,338 shares of company stock valued at $66,706,026.
A number of hedge funds have recently made changes to their positions in GH. Orbimed Advisors LLC acquired a new stake in shares of Guardant Health during the fourth quarter worth about $57,681,000. BlackRock Inc. acquired a new stake in shares of Guardant Health during the fourth quarter worth about $41,894,000. Lord Abbett & CO. LLC acquired a new stake in shares of Guardant Health during the fourth quarter worth about $20,024,000. FMR LLC acquired a new stake in shares of Guardant Health during the fourth quarter worth about $13,612,000. Finally, Geode Capital Management LLC acquired a new stake in shares of Guardant Health during the fourth quarter worth about $8,278,000. 69.15% of the stock is owned by institutional investors.
Guardant Health Company Profile
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.
Further Reading: Bollinger Bands
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.